Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

(2018) Helena J. Janse van Rensburg et al.   CANCER RESEARCH

Checkpoint inhibitors in breast cancer – Current status

(2018) Anne Polk et al.   CANCER TREATMENT REVIEWS

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

(2017) Tomas Jelinek et al.   IMMUNOLOGY

PD-L1

(2017) Anthousa Kythreotou et al.   JOURNAL OF CLINICAL PATHOLOGY

Immunotherapy in triple-negative breast cancer

(2017) Heather Katz et al.   MEDICAL ONCOLOGY

NF-κB Is a Potential Molecular Drug Target in Triple-Negative Breast Cancers

(2017) Paola Poma et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer

(2017) Sushil Kumar et al.   OncoImmunology

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP)

(2017) Xiao-Long Qian et al.   PLoS One

Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer

(2016) Xiaoxian Li et al.   BREAST CANCER RESEARCH AND TREATMENT

Current progress in immunotherapy for pancreatic cancer

(2016) Kelly Foley et al.   CANCER LETTERS

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN  That Induce PD-L1 Expression in Head and Neck Cancer

(2015) F. Concha-Benavente et al.   CANCER RESEARCH

Syntenin controls migration, growth, proliferation, and cell cycle progression in cancer cells

(2015) Rudra Kashyap et al.   Frontiers in Pharmacology

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Overexpression of syntenin enhances hepatoma cell proliferation and invasion: Potential roles in human hepatoma

(2014) XUEMIN LIU et al.   ONCOLOGY REPORTS

Novel Role of MDA-9/Syntenin in Regulating Urothelial Cell Proliferation by Modulating EGFR Signaling

(2013) S. Dasgupta et al.   CLINICAL CANCER RESEARCH

Syndecan Binding Protein (SDCBP) Is Overexpressed in Estrogen Receptor Negative Breast Cancers, and Is a Potential Promoter for Tumor Proliferation

(2013) Xiao-Long Qian et al.   PLoS One

Mda-9/syntenin Promotes Human Brain Glioma Migration through Focal Adhesion Kinase (FAK)-JNK and FAK-AKT Signaling

(2012) Dong Zhong et al.   Asian Pacific Journal of Cancer Prevention

Raf Kinase Inhibitor RKIP Inhibits MDA-9/Syntenin-Mediated Metastasis in Melanoma

(2012) S. K. Das et al.   CANCER RESEARCH

Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

(2012) Héctor Peinado et al.   NATURE MEDICINE

MDA-9/syntenin: a positive gatekeeper of melanoma metastasis

(2011) Swadesh et al.   Frontiers in Bioscience-Landmark

mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src

(2008) H. Boukerche et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA